Navigation Links
Cell and Gene Therapy Firms Grab Over $11 Billion So Far in 2021
Date:8/5/2021

There has been at least $11.2 billion in announced financing for cell and gene therapy-related companies in 2021, according to Cell and Gene Therapy Business Outlook. The new newsletter, which tracks CGT companies, noted that funding is originating from external entities such as venture capital firms and government funds along with a few IPOs. The amount is generated from 84 deals involving financing.

Early in July, Intellia Therapeutics, Inc. announced the closing of an underwritten public offering raising approximately $690 million. The company is developing novel, potentially curative therapeutics using CRISPR/Cas9 technology. Goldman Sachs & Co. LLC, Jefferies, SVB Leerink, and Barclays acted as joint book-running managers for the offering.

Also In July, Caribou Biosciences announced its initial public offering. The size of the IPO has been set at 304M. Caribou announced July 12th that the first patient has been dosed in its open-label, multicenter ANTLER Phase I clinical trial (NCT04637763) to evaluate the company’s lead product candidate, CB-010, in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL).

Other recent deals the publication tracked included:

  • Redwood City, California / Research Triangle N.C.-based Kriya Therapeutics announced it closed 100B in Series B financing. By combining advances in computer science and vector biology, Kriya is developing its SIRVE™ (System for Intelligent Rational Vector Engineering) platform for de novo vector design, sequence modification and data analysis
  • Waltham, MA-based T Scan Therapeutics, Inc. announced the pricing of its initial public offering for gross proceeds of $100.0 million. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
  • Isolere Bio, a spinout from Duke University whose technology aids biotechnology manufacturing, received $7 million dollars in seed funding from Northpond Ventures.
  • EcoR1 Capital and Farallon Capital Management provided Affinia Therapeutics $110 million in financing to further develop its proprietary gene therapy platform.
  • Talaris Therapeutics and Achilles Therapeutics announced raising $150 million and $176 million, respectively from IPOs this year.
  • Boundless Bio announced the closing of an oversubscribed $105 million for its ecDNA Harboring Oncogenes (ECHO™) companion diagnostic and related programs.
  • Haifa, Israel-based Pluristem Therapeutics Inc., received approximately $24 million from the European Investment Bank (EIB). The company is developing new product candidates for its PLX placenta-based cell therapy product candidate.

The average deal announced was pegged at $113 million by Cell and Gene Therapy Business Outlook, but there are smaller deals as well: CAMP4 Therapeutics, Rejuvenate Bio, and Adaptate Biotherapeutics received $48 million, $10 million and $18 million respectively in recent financing deals.

Cell and Gene Therapy Business Outlook is a new publication from Science and Medicine Group, which continuously tracks the deal activity of over 560 companies in cell and gene therapy. The publication also analyzes news of the day and scientific developments for business importance, and makes continuous assessments of the market for cell and gene therapy.

More information can be obtained at http://www.cellandgenetherapybusinessoutlook.com

Read the full story at https://www.prweb.com/releases/cell_and_gene_therapy_firms_grab_over_11_billion_so_far_in_2021/prweb18114459.htm.


'/>"/>
Source: PRWeb
Copyright©2021 Vocus, Inc.
All rights reserved


Related biology news :

1. Discovery may help prevent chemotherapy-induced anemia
2. Researchers reveal new more precise method of performing electroconvulsive therapy
3. New Research: Modified Citrus Pectin - A Potent Anti-Cancer Therapy
4. Mount Sinai discovers new liver cell for cellular therapy to aid in liver regeneration
5. Posttraumatic stress disorder treatment: Genetic predictor of response to exposure therapy
6. New sickle cell anemia therapy advances to Phase II clinical trials
7. An article in Cell reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer
8. No danger of cancer through gene therapy virus
9. Dendritic cell therapy improves kidney transplant survival, Pitt team says
10. Neuroblastoma: Autophagy protects from chemotherapy
11. UCLA stem cell gene therapy for sickle cell disease advances toward clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology: